This monoclonal antibody recognizes the SARS-CoV-2 Spike (B.1.1.529, Omicron Variant) RBD Domain and the S1+S2 trimeric complex to neutralize its interaction with ACE2 [Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant):ACE2 Inhibitor Screening Colorimetric Assay Kit (BPS Bioscience #78339).